Biogen taps digital therapeutics biotech for music-based therapy to help people with MS improve their walking
In the past decade, digital healthcare has been getting big — and now it’s saddling up with Big Pharma. As the latest pharma to take a swing at digital therapy, Biogen has licensed an investigational prescription therapy meant to help patients with multiple sclerosis (MS) improve their gait from MedRhythms, a Portland, ME-based biotech.
For the therapy, dubbed MR-004, MedRhythms is receiving $3 million upfront and can get up to $117.5 million more in downstream milestones, according to the press release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.